<P>&nbsp;</P> <P align=justify><STRONG>Edelris, a <A title="" href="https://www.aderly.com/pharmaceutique_biotech/index,p,100044,EN.jsp" target=_blank>medicinal chemistry company based in Lyon </A>was selected to become a partner of the pan-European drug discovery platform launched on 7th February 2013. </STRONG></P> <P align=justify><BR>The &#8364;196 million platform, called the European Lead Factory was created by a <STRONG>consortium of 30 public and private partners including large pharmaceutical companies, small and medium-sized enterprises (SMEs) and academia</STRONG>. This project, supported by the IMI (Innovative Medicines Initiative) creates unprecedented opportunities for the discovery of new medicines. Indeed, it provides public partners with an "industry-like" discovery platform, enabling them to transform academic research into high-quality drug molecules on a large scale.</P> <P align=justify>&nbsp;</P> <P align=justify>Furthermore, in order to elevate the outcome of the early drug discovery process, stakeholders such as patient organisations and global health initiatives, are invited to contribute their knowledge and networks to the consortium.</P> <P align=justify>&nbsp;</P> <P align=justify><STRONG>The 7 participating pharmaceutical companies, including Edelris, will contribute at least&nbsp; 300,000 chemical compounds from their corporate chemical collections</STRONG> and&nbsp; 200,000 novel compounds will be developed jointly by academia and SMEs.</P> <P align=justify>&nbsp;</P> <P align=justify>If the project proves successful during its initial five year funding period, the European Screening Centre and the teams of SMEs and academic institutions aim for <STRONG>a sustainable role in drug discovery and the future growth of drug development in Europe</STRONG>.<BR></P>